1. Introduction {#s0005}
===============

Vascular calcification (VC) is common in individuals with chronic kidney diseases.[@b0005] Vascular calcification is highly prevalent in patients on dialysis as 94% of the patients had aortic calcification detected by lateral abdominal radiography.[@b0010] Similarly, Jean et al.[@b0015] reported a high prevalence 83% of vascular calcifications in hemodialysis (HD) patients in spite of a long and intensive dialysis strategy and adherence to guidelines. Emad et al. reported 78% of Egyptian HD patients showing abdominal aortic calcification.[@b0020]

The pathogenesis of vascular calcifications is complex and not fully understood. It does not only consist of a simple precipitation of calcium and phosphorus, but also involves an active and modifiable process. Vascular calcification in chronic kidney diseases (CKD) may be interpreted as the result of the dysregulation of the equilibrium between calcification promoters and inhibitors in which several uremic factors, including abnormalities in the mineral metabolism, are implicated.[@b0025]

Osteoprotegerin (OPG) is a cytokine of the tumor necrosis factor (TNF) receptor superfamily and is classed as an osteoclastogenesis inhibitory factor. OPG is expressed widely in many tissues besides osteoblasts, including spleen, bone marrow, heart, liver, and kidney.[@b0030] The plasma level of OPG could serve as a surrogate marker of progression of atherosclerosis and calcification in patients with end-stage renal disease.[@b0035]

It has also been demonstrated that serum Osteoprotegerin (OPG) levels are correlated with the severity of coronary artery disease and constitute an independent risk factor of the progression of atherosclerosis.[@b0040] A study by Morena et al. suggests that there is a significant correlation between elevated serum OPG levels and cardiovascular mortality.[@b0045]

We aimed to investigate the relation between osteoprotegerin level and cardiovascular calcification in hemodialysis patients.

2. Patients and methods {#s0010}
=======================

The study was carried out for a period of one year from January 2014 to January 2015 at El-Galaa Military Hospital. A total of 60 patients with clinically stable end stage kidney disease (ESKD) were enrolled in this cross-sectional study. According to lateral abdominal X-ray, we selected 30 patients with abdominal aortic calcification (group A) and they had been compared with another 30 patients selected without abdominal aortic calcification (group B). All patients were dialyzed via AVF three times a week for four hour session using polysulfone high flux dialyzer 1.6 m^2^ surface area, with dialysate flow 500 ml/min and dialysate calcium concentration 1.25 mmol/l, using heparin as anticoagulant with tailored doses according to each case and bicarbonate based dialysate. The adequacy of dialysis was assessed using Kt/V formula (K is patient clearance, t dialysis time, V urea space).[@b0050] Patients with the following criteria were included in the study: patients older than 25 years; parathyroid hormone (PTH) \> 300 pg/ml; serum calcium \>8.4 mg/dl and calcium phosphorus product \>50 mg/dl. On the other hand, patients subjected to parathyroidectomy; severely anemic patients (Hb \< 7 g/dl); patients with advanced cardiac dysfunction (EF% \< 35%); patients on oral anticoagulants; and patients on regular hemodialysis less than 6 months and diabetics were excluded.

Each patient underwent full clinical evaluation, serum calcium, phosphorus, alkaline phosphatase albumin, lipid profile, PTH, serum creatinine, serum urea, Serum uric acid, C-reactive protein (CRP), and hemoglobin. Osteoprotegerin samples were collected before dialysis and stored at −80 °C until use. Serum OPG samples were estimated by the ELISA kit provided by Phoenix Pharmaceuticals, Prague-Czech. All patients were informed about the content of the study and gave their written approvals before enrollment. All procedures were performed in accordance with the ethical standards of Al-Azhar University's committee on human experiments.

Radiological evaluation: It was performed through Echocardiography to measure different cardiac parameters especially left ventricular diameters and ejection fraction. Lateral abdominal X-radiography of the aorta for grading of calcifications was as follows: 0, no aortic calcific deposits; 1, small scattered calcific deposits less than one-third of the corresponding length of the vertebral level; 2, medium quantity of calcific deposits about one-third or more, but less than two-thirds of the corresponding vertebral length; 3, severe quantity of calcifications of more than two-thirds or more of the corresponding vertebral lengths. To detect abdominal aortic calcification we used a validated 24-point abdominal aortic calcification score (AACS). For the 24-point score, calcified deposits along the anterior and posterior longitudinal walls of the abdominal aorta adjacent to each lumbar vertebra from L1 to L4 were assessed using the midpoint of the intervertebral space above and below the vertebrae as the boundaries. The scores, obtained separately for the anterior and posterior walls, resulted in a range from 0 to 6 for each vertebral level and 0 to 24 for the total score.[@b0055] Multi-slice CT scan (MDCT) was used to measure coronary artery calcification score using Agatston score. The score was calculated using a weighted value assigned to the highest density of calcification in a given coronary artery. The density was measured in Hounsfield units, and score of 1 for 130--199 HU, 2 for 200--299 HU, 3 for 300--399 HU, and 4 for 400 HU and greater. This weighted score was then multiplied by the area (in square millimeters) of the coronary calcification. The tomographic slices of the heart were 3 mm thick and average about 64 slices from the coronary artery ostia to the inferior wall of the heart. The calcium score of every calcification in each coronary artery for all of the tomographic slices was then summed up to give the total coronary artery calcium score (CAC score).[@b0060]

3. Statistical methods {#s0015}
======================

All statistical calculations were done using computer programs SPSS (Statistical Package for the Social Science; SPSS Inc., Chicago, IL, USA) version 15 for Microsoft Windows. Data are presented as mean and SD. In addition, parametric tests for comparison of numerical variables between the study groups were done using Independent Samples T Test. For comparing categorical data Chi-squared test was performed. Correlation between numeric variables was done using Pearson's correlation equation. Stepwise multiple regression analysis was for detection of vascular calcifications predictors. P values less than 0.05 was considered statistically significant.

4. Results {#s0020}
==========

Characteristics of study groups are summarized in [Table 1](#t0005){ref-type="table"}. Both groups were matched regarding age, gender, body mass index (BMI), original kidney disease. The patients with vascular calcifications have higher duration of hemodialysis, serum phosphorus, calcium-phosphorus product, CRP and serum uric acid. Also, the patients with vascular calcifications have high left ventricular mass index (LVMI) and low ejection fraction (IF). These changes are associated with increased OPG levels in patients with vascular calcifications ([Table 1](#t0005){ref-type="table"}). There are positive correlations between OPG and age, duration of hemodialysis, serum phosphorus, calcium phosphorus product, alkaline phosphatase, PTH, CRP, serum uric acid, and LDL and there is negativity with serum calcium. In addition, OPG correlated positively with AACS, CACS and LVMI while negatively with ejection fraction ([Table 2](#t0010){ref-type="table"}). Stepwise multiple regression analysis by using of AACs and CACs as dependent variables separately revealed that the predictors of both abdominal aortic calcifications and coronary artery calcifications are CRP, cholesterol and alkaline phosphatase levels ([Table 3](#t0015){ref-type="table"}, [Table 4](#t0020){ref-type="table"}), and the remaining variables are excluded.Table 1Demographic, laboratory and echocardiographic data of the patients.Group A (*n* = 30)Group B (*n* = 30)*P* valueMean age (years) ± SD56.7 ± 10.556.5 ± 8.4\>0.05Sex (male/female)13/1714/16\>0.05Duration of hemodialysis/month (mean ± SD)76.9 ± 29.234.5 ± 16.7\<0.005BMI g/m^2^ (mean ± SD)26.6 ± 4.328 ± 3.4\>0.05  *Original kidney disease (n &%)*Hypertension11(36.7%)9(30%)Chronic pyelonephritis5(16.7%)4(13.3%)Chronic glomerulonephritis5(16.7%)7(23.3%)Obstructive uropathy4(13.3%)2(6.7%)\>0.05APCKD2(6.7%)3(10%)Unknown3(10%)5(16.7%)  OPG (pg/ml) (M ± SD)714.30 ± 433332.36 ± 176\<0.001  OPG (pg/ml) Male477 ± 373 Female560 ± 388\>0.05  Creatinine (mg/dl) (M ± SD)8.6 ± 1.78.8 ± 1.5\>0.05Urea (mg/dl) (M ± SD)174 ± 30167 ± 40\>0.05Kt/V(M ± SD)1.24 ± 0.11.28 ± 0.12\>0.05Hemoglobin (g/dl) (M ± SD)9.45 ± 0.7210.02 ± .61\>0.05C-reactive protein (M ± SD)5.26 ± 1.83.46 ± 0.92\<0.001Serum phosphorus (mg/dl) (M ± SD)6.2 ± 0.775.7 ± .0.53\<0.001Serum calcium (mg/dl) (M ± SD)9.6 ± 0.89.4 ± 0.7\>0.05Serum albumin(g/dl) (M ± SD)3.56 ± 0.553.61 ± 0.53\>0.05Ca-Ph product (mg/dl) (M ± SD)59.6 ± 4.854 ± 3.9\<0.001Serum PTH(pg/ml) (M ± SD)550 ± 180471 ± 160\>0.05Alkaline phosphatase (IU/dl) (M ± SD)163.6 ± 30155.7 ± 20\>0.05Serum cholesterol (mg/dl)225 ± 21206 ± 50\>0.05Serum triglycerides (mg/dl)162 ± 25164.9 ± 25\>0.05Serum LDL (mg/dl) (M ± SD)136 ± 21129 ± 22\>0.05Serum HDL mg/dl) (M ± SD)40 ± 6.539.9 ± 5.5\>0.05Serum uric acid (mg/dl) (M ± SD)6.4 ± 1.35.6 ± 1.1\<0.05Left ventricular mass index (g/m^2^) (M ± SD)265.4 ± 41.3214.6 ± 50\<0.001Ejection fraction % (M ± SD)56.1 ± 662.4 ± 6.9\<0.001Table 2Correlations between OPG, AACS and CACS other laboratory variables.Aortic calcification scoreCoronary calcification scoreOPG (pg/dl)RSig.RSig.RSig.Age.585[\*\*](#tblfn2){ref-type="table-fn"}.001.516[\*\*](#tblfn2){ref-type="table-fn"}.004.371[\*\*](#tblfn2){ref-type="table-fn"}.004Duration of HD.728[\*\*](#tblfn2){ref-type="table-fn"}.000.734[\*\*](#tblfn2){ref-type="table-fn"}.000.727[\*\*](#tblfn2){ref-type="table-fn"}.000BMI.290.120.301.106.086.516Serum creatinine−.203.282−.173.361−.103.432Blood urea−.166.379−.231.218−.087.507Kt/V−.167.378−.190.315−.086.513Serum Phosphorus.563[\*\*](#tblfn2){ref-type="table-fn"}.001.420[\*](#tblfn1){ref-type="table-fn"}.021.651[\*\*](#tblfn2){ref-type="table-fn"}.000Serum calcium−.584[\*\*](#tblfn2){ref-type="table-fn"}.001−.508[\*\*](#tblfn2){ref-type="table-fn"}.004−.342[\*\*](#tblfn2){ref-type="table-fn"}.008ca × po4 product.240.201.105.581.494[\*\*](#tblfn2){ref-type="table-fn"}.000Serum alkaline phosphatase.743[\*\*](#tblfn2){ref-type="table-fn"}.000.715[\*\*](#tblfn2){ref-type="table-fn"}.000.505[\*\*](#tblfn2){ref-type="table-fn"}.000PTH.612[\*\*](#tblfn2){ref-type="table-fn"}.000.461[\*](#tblfn1){ref-type="table-fn"}.010.541[\*\*](#tblfn2){ref-type="table-fn"}.000Serum albumin−.086.652−.082.667−.177.177Serum cholesterol.407[\*](#tblfn1){ref-type="table-fn"}.026.384[\*](#tblfn1){ref-type="table-fn"}.036.239.066Serum triglycerides.364[\*](#tblfn1){ref-type="table-fn"}.048.432[\*](#tblfn1){ref-type="table-fn"}.017.007.959LDL.597[\*\*](#tblfn2){ref-type="table-fn"}.000.519[\*\*](#tblfn2){ref-type="table-fn"}.000.359[\*\*](#tblfn2){ref-type="table-fn"}.005HDL−.468[\*\*](#tblfn2){ref-type="table-fn"}.009−.381[\*](#tblfn1){ref-type="table-fn"}.038−.278[\*](#tblfn1){ref-type="table-fn"}.031Hb %−.234.069−.196.232−.269.058CRP.819[\*\*](#tblfn2){ref-type="table-fn"}.000.760[\*\*](#tblfn2){ref-type="table-fn"}.000.603[\*\*](#tblfn2){ref-type="table-fn"}.000Serum uric acid.285.127.298.110.343[\*\*](#tblfn2){ref-type="table-fn"}.007Ejection fraction−.624[\*\*](#tblfn2){ref-type="table-fn"}.000−.507[\*\*](#tblfn2){ref-type="table-fn"}.004−.494[\*\*](#tblfn2){ref-type="table-fn"}.000LVMI.624[\*\*](#tblfn2){ref-type="table-fn"}.000.436[\*](#tblfn1){ref-type="table-fn"}.016.609[\*\*](#tblfn2){ref-type="table-fn"}.000Aortic calcification score.788[\*\*](#tblfn2){ref-type="table-fn"}.000Coronary calcification score.626[\*\*](#tblfn2){ref-type="table-fn"}.000[^1][^2]Table 3Stepwise multiple regression analysis by using all tested variables and abdominal aortic calcification score as dependent variables.ModelUnstandardized coefficientsStandardized coefficients*t*Sig.BStd. errorBeta1(Constant)−1.2991.202−1.080.289CRP1.634.216.8197.552.000  2(Constant)−14.3483.524−4.071.000CRP1.578.177.7918.893.000Serum cholesterol (mg/dl).059.015.3433.856.001  3(Constant)−18.4983.479−5.317.000CRP1.092.235.5474.644.000Serum cholesterol (mg/dl).061.014.3534.442.000Serum alkaline phosphatase (IU/dl).039.014.3292.801.009Table 4Stepwise multiple regression analysis by using all tested variables and coronary artery calcification score as dependent variable.ModelUnstandardized coefficientsStandardized coefficients*t*Sig.BStd. errorBeta1(Constant)−334.350242.299−1.380.179CRP269.79443.597.7606.188.0002(Constant)−2532.703766.913−3.302.003CRP260.48738.623.7346.744.000Serum Cholesterol (mg/dl)9.9663.339.3252.985.0063(Constant)−3343.456778.820−4.293.000CRP165.42652.642.4663.142.004Serum Cholesterol (mg/dl)10.3133.071.3363.358.002Serum alkaline phosphatase (IU/dl)7.5343.081.3622.445.022

5. Discussion {#s0025}
=============

Several mechanisms have been implicated for the high prevalence of vascular calcification in CKD, including the high burden of conventional cardiovascular risks such as hypertension, dyslipidemia, bone and mineral disorders such as calcium load and secondary hyperparathyroidism (SHPT), Chronic inflammation such as high level of pro inflammatory cytokines and deficiency of anticalcemic factors.[@b0040]

In this current study, we found that all patients with abdominal aortic calcification have coronary artery calcification and its extent directly correlated with abdominal aortic calcification. The patients with vascular calcification have higher serum phosphorus and calcium phosphorus (Ca × P) product than those without vascular calcifications. These results agree with several studies. Elevated serum phosphorus is now recognized as a major risk factor for cardiovascular events in stage 4 chronic kidney disease (CKD 4) and the general population.[@b0065] Mortality in ESKD patients is strongly correlated with serum phosphorus levels \>5.5 mg/dl.[@b0070] Also, relatively small elevations in serum phosphorus in the high normal range (3.5--4.5 mg/dl) have been correlated with increased risk of cardiovascular and all-cause mortality in CKD patients and the general population with normal renal function.[@b0075] In addition, several studies that concluded that, an increased calcium phosphorus product and hyperphosphatemia are thought to be a key determinant of cardiovascular mortality and progression factors of unwanted calcifications in uremia.[@b0080], [@b0085], [@b0090], [@b0095], [@b0100]

The role of PTH is also unclear, PTH Fragments 1--34 have been shown to inhibit calcification in a murine model of atherosclerotic vascular calcification[@b0105] but PTH 7--84 may act to increase vascular calcification[@b0110] and high PTH levels are often associated with high calcification scores.[@b0115] In the current study, serum calcium, PTH, and alkaline phosphatase of patients with VC and those without VC were a like comparable and this in concordance with Graciolli et al.[@b0120] demonstrated that PTH itself is not able to induce vascular calcification but has a synergistic effect with the phosphorus probably due to an indirect and deleterious effect associated with bone remodeling and osteoclastic activity. In addition, Kazuhiro et al.[@b0125] found that serum calcium, serum phosphorus and the calcium phosphorus product were not associated with aortic calcification and this may be related to the overall good mineral control of their patients.

In addition, we found significantly high CRP and serum uric acid among patients with vascular calcifications. It is well known that inflammation has a key role in coronary artery disease and other manifestations of atherosclerosis.[@b0130] CRP was significantly associated with the presence of vascular calcification in both aorta and hand arteries.[@b0135] Serum uric acid above 6 mg/dl is associated with an increased risk of calcification and cardiovascular adverse events in CKD patients in dialysis,[@b0140] while Caliskan et al.[@b0145] and Turkmen et al.[@b0150] found no correlation between hs-CRP levels and CACS.

Several epidemiological studies suggested that elevated serum levels of OPG were associated with the vascular risk and calcification.[@b0155], [@b0160], [@b0045], [@b0165], [@b0170], [@b0175] In the current study the levels of circulating OPG are significantly higher among hemodialysis patients with vascular calcifications. The mechanism that can explain the association of elevated OPG levels with vascular calcification in hemodialysis is still controversial. It can be elevated as a result of vascular damage,[@b0155] or it is elevated as it has a role in calcification process itself,[@b0165] and it may be as a compensatory protective response to progression of vascular calcification. Also, it was stated that circulating OPG level in CKD patients may indicate a state of resistance to OPG action due to the uremic condition,[@b0110] or it may be uremic toxin that increases the skeletal resistance to PTH.[@b0160], [@b0045] The elevated OPG dramatically reduced after successful renal transplantation.[@b0180]

Moreover, we noticed that OPG levels are related to age, duration of hemodialysis, calcium, phosphorus, alkaline phosphatase, calcium phosphorus product, PTH, CRP, HDL and LDL. Similarly, Ozkok et al.[@b0185] reported that serum OPG levels were significantly correlated with age and duration of dialysis and serum albumin levels. Azar et al. reported the relationship of OPG with age, calcium levels while PTH was not shown to be significant.[@b0190] The association of CRP with OPG has been reported by Kiech et al.[@b0195] in which serum CRP levels had a positive correlation with serum OPG levels. Kendrick and Chonchol[@b0200] found a positive weak correlation between OPG and both total cholesterol and triglycerides only in the obese, and these correlations disappeared after adjustment for age. Junichiro et al.[@b0160] and Morena et al.[@b0165] found no significant correlation between OPG level and calcium and phosphate, PTH but the low number of patients lessens the strength of this study.

In the present study, the predictors for the presence of abdominal aortic calcifications and coronary artery calcifications are CRP, cholesterol and alkaline phosphatase. There are several lines of evidence showing that CAC is associated with systemic inflammation[@b0205], [@b0210], [@b0215], [@b0220] as the component of the malnutrition-inflammation-atherosclerosis syndrome. Atherosclerosis frequently coexists with systemic inflammation especially in hemodialysis diabetic patients.[@b0225]

Abdominal aortic calcification deposits are a marker of subclinical atherosclerotic disease and an independent predictor of subsequent vascular morbidity and mortality and the predictors for the presence and severity of abdominal aortic calcification were age, duration of dialysis and history of cardiovascular disease.[@b0230] The results of Pencak et al.'s study demonstrated that AAC preceded the occurrence of CAC and revealed differences in factors favoring their development. Age and hemodialysis vintage were equally (OR  =  1.13 and 1.14) important for the occurrence of CAC, while only age was a major (OR  =  1.20) predictor of the occurrence of AAC.[@b0235]

AACS have positive correlations with age, duration of hemodialysis, serum phosphorus, corrected serum calcium and calcium-phosphorus product, iPTH, cholesterol, triglycerides, low density lipoprotein (LDL), CRP and serum uric acid, and negative correlation with high density lipoprotein (HDL). Moldovan et al.[@b0240] found that the presence of vascular calcification was associated with age, gender, diabetes, dialysate calcium, serum calcium and vitamin D treatments, calcium - phosphorus product, PTH and CRP. Also, Nigel et al.[@b0010] reported that the presence and severity of AAC were related to age, duration of dialysis and the presence of cardiovascular disease, but there was no significant relationship between AACS and serum markers of mineral metabolism (phosphate, calcium, PTH, 25-hydroxy vitamin D), lipids, C-reactive protein or the presence of diabetes. Moreover, Nishizawa et al.[@b0245] concluded that the significant factors affecting vascular calcification were advanced age, longer duration of hemodialysis, increased phosphate concentrations and lower predialysis diastolic pressure.

In the current study, CACS directly correlated with age, duration of hemodialysis, phosphorus, calcium~,~ PTH, alkaline phosphatase and CRP, cholesterol, triglycerides, LDL, and inversely with HDL. These results have been documented by many studies[@b0080], [@b0165], [@b0170], [@b0175], [@b0110]. In contrast, Nitta et al.[@b0210], Berenzin and Kremzer[@b0250] reported that the CACS had no significant correlation with serum calcium, serum phosphorus and PTH. The heterogeneity of the study population, study design as single baseline laboratory value may lessen the strength of some of the significant predictors of CAC especially those that vary widely day-to-day.

Aortic calcification scores and coronary artery calcification scores correlated positively with OPG levels among our patients. Our results supported by many studies noticed strong association between OPG levels and vascular calcification in coronary arteries in patients with CKD[@b0155], [@b0165], [@b0255] as well as in the aorta for patients with ESRD[@b0015], [@b0240]. Both progression of vascular calcification[@b0260], [@b0265] and cardiovascular events are related to high level of OPG in patients with CKD.[@b0165], [@b0270], [@b0275]

6. Conclusions {#s0030}
==============

Our results suggested that OPG may be involved in progression of vascular calcification in patients undergoing hemodialysis. Since, we live in the era of continuously emerging biomarkers for detection of cardiovascular calcification that differs in their sensitivity and specificity. Therefore, serum OPG can be used as recent, simple, easily performed non-invasive biomarker mirroring vascular calcification in hemodialysis patients as it is parallel with disease progression and it can be added to a panel or scoring system that might present a practical and non-invasive tool to detect cardiovascular calcification in hemodialysis patients.
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[^1]: Correlation is significant at the 0.05 level (2-tailed).

[^2]: Correlation is significant at the 0.01 level (2-tailed).
